{
    "nctId": "NCT00527826",
    "title": "A 12 Month Open-label Randomized Parallel Group Study to Investigate the Influence of Salmeterol Xinafoate/Fluticasone Propionate Either in Fixed Combination or Separately Via Diskus Inhalers on the Course of the Disease and Frequency of Exacerbations in Subjects With Severe and Very Severe COPD.",
    "symPyJSON": {
        "type": "and",
        "operands": [
            {
                "type": "and",
                "operands": [
                    {
                        "type": "variable",
                        "value": "Subject must have a diagnosis of COPD based on the American Thoracic Society (ATS)/ European Respiratory Society (ERS) criteria."
                    },
                    {
                        "type": "or",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Male subject aged >=40 years"
                            },
                            {
                                "type": "and",
                                "operands": [
                                    {
                                        "type": "variable",
                                        "value": "Female subject aged >=40 years"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Females must be of Non Child Bearing Potential"
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "type": "variable",
                        "value": "Have diagnosed COPD stage III or IV according to GOLD criteria: a baseline post-bronchodilator Forced Expiratory Volume, measured at 1 second (FEV1) <50% of predicted normal and a baseline post-bronchodilator FEV1/Inspiratory Vital Capacity (IVC) ratio <70%."
                    },
                    {
                        "type": "variable",
                        "value": "Have experienced at least 2 moderate or severe COPD exacerbations leading to medical consultation within the 12 months preceding Visit 1."
                    },
                    {
                        "type": "variable",
                        "value": "Have stable COPD medication within 4 weeks prior to Visit 1."
                    },
                    {
                        "type": "variable",
                        "value": "Current or ex-smokers with a smoking history of at least 10 pack years."
                    },
                    {
                        "type": "variable",
                        "value": "Are currently managed at home, are ambulatory and able to travel to the clinic."
                    },
                    {
                        "type": "variable",
                        "value": "A signed and dated written informed consent is obtained prior to participation."
                    },
                    {
                        "type": "variable",
                        "value": "Able to comply with the requirements of the protocol and be available for study visits over 52 weeks."
                    },
                    {
                        "type": "variable",
                        "value": "Must have minimum age of 40 Years"
                    }
                ]
            },
            {
                "type": "not",
                "operands": [
                    {
                        "type": "or",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Known other respiratory disorders or signs for other respiratory disorders (e.g. asthma, lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis, bronchoectasis)."
                            },
                            {
                                "type": "variable",
                                "value": "Known history of significant inflammatory disease, other than COPD (e.g. rheumatoid arthritis and systemic lupus erythematosus)."
                            },
                            {
                                "type": "variable",
                                "value": "Known to be severely alpha-1-antitrypsin deficient (PI SZ or ZZ)"
                            },
                            {
                                "type": "variable",
                                "value": "Having undergone lung surgery or subjects scheduled for surgery."
                            },
                            {
                                "type": "variable",
                                "value": "Concurrent medication from Visit 1 and for the duration of the study with any of the prohibited medications: monoamine oxidase inhibitors and tricyclic antidepressants, and ritonavir."
                            },
                            {
                                "type": "variable",
                                "value": "Subjects receiving chronic or prophylactic antibiotic therapy."
                            },
                            {
                                "type": "variable",
                                "value": "Serious, uncontrolled disease likely to interfere with the study or impact on subject safety."
                            },
                            {
                                "type": "variable",
                                "value": "Have, in the opinion of the investigator, evidence of alcohol, drug or solvent abuse."
                            },
                            {
                                "type": "variable",
                                "value": "History of depression."
                            },
                            {
                                "type": "variable",
                                "value": "History or presence of clinically significant drug sensitivity or clinically significant allergic reaction to corticosteroids or salmeterol."
                            },
                            {
                                "type": "variable",
                                "value": "Moderate or severe COPD exacerbation within the 4 weeks prior to Visit 1"
                            },
                            {
                                "type": "variable",
                                "value": "Lower respiratory tract infection within the 4 weeks prior to Visit 1."
                            },
                            {
                                "type": "variable",
                                "value": "Pregnant or lactating female and female of childbearing potential."
                            },
                            {
                                "type": "variable",
                                "value": "Subject is a participating investigator, sub-investigator, study coordinator, or other employee of a participating investigator, or is an immediate family member of the before mentioned. Subject is an employee of GlaxoSmithKline (GSK)."
                            },
                            {
                                "type": "variable",
                                "value": "Subject participated in an investigational drug study within 30 days prior to Visit 1"
                            }
                        ]
                    }
                ]
            }
        ]
    },
    "symPyExpression": "And(Symbol('A signed and dated written informed consent is obtained prior to participation.'), Symbol('Able to comply with the requirements of the protocol and be available for study visits over 52 weeks.'), Symbol('Are currently managed at home, are ambulatory and able to travel to the clinic.'), Symbol('Current or ex-smokers with a smoking history of at least 10 pack years.'), Symbol('Have diagnosed COPD stage III or IV according to GOLD criteria: a baseline post-bronchodilator Forced Expiratory Volume, measured at 1 second (FEV1) <50% of predicted normal and a baseline post-bronchodilator FEV1/Inspiratory Vital Capacity (IVC) ratio <70%.'), Symbol('Have experienced at least 2 moderate or severe COPD exacerbations leading to medical consultation within the 12 months preceding Visit 1.'), Symbol('Have stable COPD medication within 4 weeks prior to Visit 1.'), Symbol('Must have minimum age of 40 Years'), Symbol('Subject must have a diagnosis of COPD based on the American Thoracic Society (ATS)/ European Respiratory Society (ERS) criteria.'), Or(Symbol('Male subject aged >=40 years'), And(Symbol('Female subject aged >=40 years'), Symbol('Females must be of Non Child Bearing Potential'))), Not(Or(Symbol('Concurrent medication from Visit 1 and for the duration of the study with any of the prohibited medications: monoamine oxidase inhibitors and tricyclic antidepressants, and ritonavir.'), Symbol('Have, in the opinion of the investigator, evidence of alcohol, drug or solvent abuse.'), Symbol('Having undergone lung surgery or subjects scheduled for surgery.'), Symbol('History of depression.'), Symbol('History or presence of clinically significant drug sensitivity or clinically significant allergic reaction to corticosteroids or salmeterol.'), Symbol('Known history of significant inflammatory disease, other than COPD (e.g. rheumatoid arthritis and systemic lupus erythematosus).'), Symbol('Known other respiratory disorders or signs for other respiratory disorders (e.g. asthma, lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis, bronchoectasis).'), Symbol('Known to be severely alpha-1-antitrypsin deficient (PI SZ or ZZ)'), Symbol('Lower respiratory tract infection within the 4 weeks prior to Visit 1.'), Symbol('Moderate or severe COPD exacerbation within the 4 weeks prior to Visit 1'), Symbol('Pregnant or lactating female and female of childbearing potential.'), Symbol('Serious, uncontrolled disease likely to interfere with the study or impact on subject safety.'), Symbol('Subject is a participating investigator, sub-investigator, study coordinator, or other employee of a participating investigator, or is an immediate family member of the before mentioned. Subject is an employee of GlaxoSmithKline (GSK).'), Symbol('Subject participated in an investigational drug study within 30 days prior to Visit 1'), Symbol('Subjects receiving chronic or prophylactic antibiotic therapy.'))))"
}